Drug intelligence / Profile preview

KAM1403

Development stage: Unknown
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

KAM1403, also referred to as **Oxyflower Gel**, is a topical gel investigated for its potential to treat **radiation dermatitis** and **pericoronitis**. Its mechanism of action and specific pharmacological class are not disclosed in publicly available sources. The product has undergone clinical studies to evaluate its safety and efficacy as a coadjuvant treatment in pericoronitis as well as to reduce the symptoms of mild to moderate radiation dermatitis. It is administered topically as a gel preparation[1][3][5][6].

Brand names: KAM1403 GelKAM-1403 GelKAM 1403 Gel
Other names: Oxyflower Gel

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on KAM1403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAM1403.

Explore the full profile